JP2002536331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002536331A5 JP2002536331A5 JP2000596937A JP2000596937A JP2002536331A5 JP 2002536331 A5 JP2002536331 A5 JP 2002536331A5 JP 2000596937 A JP2000596937 A JP 2000596937A JP 2000596937 A JP2000596937 A JP 2000596937A JP 2002536331 A5 JP2002536331 A5 JP 2002536331A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- isozyme
- inhibitor
- inducer
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- 108010044467 Isoenzymes Proteins 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 13
- 239000000411 inducer Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000000890 drug combination Substances 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- -1 budenoside Chemical compound 0.000 description 8
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 8
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 6
- 229960004166 diltiazem Drugs 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 4
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 4
- 229960000648 digitoxin Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 4
- 229960004773 losartan Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 4
- 229960001404 quinidine Drugs 0.000 description 4
- 229960001722 verapamil Drugs 0.000 description 4
- 229960005080 warfarin Drugs 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 4
- 229960002911 zonisamide Drugs 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- WQFIAVZQVYASHZ-BYPYZUCNSA-N (2s)-5-(diaminomethylideneamino)-2-(hydroxyamino)pentanoic acid Chemical compound NC(=N)NCCC[C@H](NO)C(O)=O WQFIAVZQVYASHZ-BYPYZUCNSA-N 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- RWZYEKXHAQMRIO-UHFFFAOYSA-N 2,2-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C(O)(O)CCCC=C RWZYEKXHAQMRIO-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
- 229960002837 benzphetamine Drugs 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
- 229960005352 gestodene Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960002135 sulfadimidine Drugs 0.000 description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229950001074 zatosetron Drugs 0.000 description 2
- MMTXSCWTVRMIIY-PHDIDXHHSA-N (3r,5s)-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)C=C MMTXSCWTVRMIIY-PHDIDXHHSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
| GB9902593.4 | 1999-02-06 | ||
| GB9921064.3 | 1999-09-08 | ||
| GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
| GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
| GB9921063.5 | 1999-09-08 | ||
| PCT/GB2000/000278 WO2000045817A1 (en) | 1999-02-06 | 2000-02-01 | Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007195798A Division JP2007277267A (ja) | 1999-02-06 | 2007-07-27 | （ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシヘプツ−６−エン酸と、ｐ４５０アイソザイム３ａ４の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002536331A JP2002536331A (ja) | 2002-10-29 |
| JP2002536331A5 true JP2002536331A5 (enExample) | 2006-10-05 |
Family
ID=27269637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596937A Pending JP2002536331A (ja) | 1999-02-06 | 2000-02-01 | （ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシヘプツ−６−エン酸と、ｐ４５０アイソザイム３ａ４の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
| JP2007195798A Pending JP2007277267A (ja) | 1999-02-06 | 2007-07-27 | （ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシヘプツ−６−エン酸と、ｐ４５０アイソザイム３ａ４の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007195798A Pending JP2007277267A (ja) | 1999-02-06 | 2007-07-27 | （ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシヘプツ−６−エン酸と、ｐ４５０アイソザイム３ａ４の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6982157B1 (enExample) |
| EP (1) | EP1185274B1 (enExample) |
| JP (2) | JP2002536331A (enExample) |
| KR (2) | KR20060117381A (enExample) |
| CN (1) | CN1165310C (enExample) |
| AR (1) | AR029333A1 (enExample) |
| AT (1) | ATE282415T1 (enExample) |
| AU (1) | AU767304B2 (enExample) |
| BR (1) | BR0007999A (enExample) |
| CA (1) | CA2358632C (enExample) |
| CZ (1) | CZ301296B6 (enExample) |
| DE (1) | DE60015965T2 (enExample) |
| EE (1) | EE04929B1 (enExample) |
| EG (1) | EG23858A (enExample) |
| ES (1) | ES2232418T3 (enExample) |
| GB (1) | GB0000710D0 (enExample) |
| ID (1) | ID30485A (enExample) |
| IL (1) | IL144715A0 (enExample) |
| IS (1) | IS2337B (enExample) |
| MX (1) | MXPA01007905A (enExample) |
| MY (1) | MY130606A (enExample) |
| NO (1) | NO320745B1 (enExample) |
| NZ (1) | NZ512982A (enExample) |
| PL (1) | PL198034B1 (enExample) |
| PT (1) | PT1185274E (enExample) |
| TR (1) | TR200102228T2 (enExample) |
| TW (1) | TWI282738B (enExample) |
| WO (1) | WO2000045817A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| JP5069001B2 (ja) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | フィブラートを含む固体投与形態 |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2005271413A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| EP1948600B1 (en) * | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Liver targeted conjugates |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
| CN112955965B (zh) * | 2018-06-14 | 2024-04-09 | 阿斯利康(英国)有限公司 | 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法 |
| US20220273652A1 (en) | 2019-07-31 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| DK0521417T3 (da) * | 1991-07-02 | 1995-03-27 | Benckiser Gmbh Joh A | Sammenklappelig forrådsflaske |
| JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
| FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Ceased
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Ceased
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko not_active Ceased
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002536331A5 (enExample) | ||
| AU767304B2 (en) | Drug combinations comprising (E) -7 - (4 -(4 -fluorophenyl) -6 - isopropyl -2 - (methyl (methylsulfonyl) amino) pyrimidin -5 -yl) (3R,5S) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 | |
| JP2023519959A (ja) | デキストロメトルファンの経皮送達 | |
| Fruzzetti et al. | Review of clinical experience with estradiol in combined oral contraceptives | |
| EP1448205B1 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| JP2001019638A (ja) | 高速吸収性液体組成物 | |
| US20170246183A1 (en) | Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen | |
| NO20031409D0 (no) | Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse | |
| Mallareddy et al. | Drospirenone, a new progestogen, for postmenopausal women with hypertension | |
| David et al. | Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability | |
| JP2006524190A5 (enExample) | ||
| RU2001124666A (ru) | Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s) -3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4 | |
| WO2005058341A3 (en) | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases | |
| JP2023521653A (ja) | 皮下用生分解性リザーバ装置のための多剤製剤 | |
| WO2005107809A3 (en) | Antimycobacterial pharmaceutical composition comprising an antitubercular drug | |
| WO2004041181A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| SE9902936D0 (sv) | Pharmaceutical compositions | |
| KR950703958A (ko) | Hiv 감염증을 치료하기 위한,다른 비뉴클레오사이드 역 전사효소 억제제와 혼합된 bhap 화합물의 용도(use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection) | |
| Perry et al. | Medication interactions with contraceptives | |
| JP2008519073A (ja) | チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法 | |
| Levy et al. | CML-375: AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations | |
| Crofskey | Novel integrase inhibitor promising in triple-class resistant HIV-1 | |
| Hartshorn | Drug Interaction: III. Classes of Drugs and Their Interactions: Antihistamines | |
| Schulman | Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia | |
| HU226062B1 (en) | Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |